Mode
Text Size
Log in / Sign up
N/A N=22 Basic Science

The Effect of Electronic Cigarette Liquid Characteristics in Smokers.

Electronic Cigarettes

Enrolled (actual)
22
Serious AEs
Results posted
Dec 2022
Primary outcome: Primary: Plasma Nicotine Concentration — 12.32; -0.22; 7.09; 5.85 ng/ml

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Own Brand Cigarette (Other); ECIG 15 mg nicotine, sweetened (Other); ECIG 15 mg nicotine, unsweet (Other); ECIG 0 mg nicotine, sweetened (Other); ECIG 0 mg nicotine, unsweet (Other)
Age
Adult · 21+ yrs
Sex
All
Sponsor
Virginia Commonwealth University
Primary completion
Dec 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
Plasma Nicotine Concentration
12.32; -0.22; 7.09; 5.85; -0.29
PRIMARY
Progressive Ratio Task - Breakpoint
416.07; 307.29; 336.43; 492.86; 812.86
PRIMARY
Progressive Ratio Task - Number of Puffs
7.64; 6.21; 5.07; 7.21; 9.93
PRIMARY
Progressive Ratio Task - Latency
161176.93; 390300.43; 315803.79; 263130.86; 6500.64
SECONDARY
Puff Volume
207.17; 233.47; 130.57; 166.51; 65.12
SECONDARY
Puff Duration
2.54; 2.74; 1.60; 1.94; 2.06

Summary

The purpose of this study is to determine differences in nicotine delivery, user behaviors, subjective effects, and physiological effects, when cigarette smokers use an electronic cigarette with different nicotine (and sweetener) concentrations relative to using their own brand of cigarettes.

Eligibility Criteria

Inclusion Criteria-- Participants must be:

  • Healthy (determined by self-report)
  • Between the ages of 21-55 years old
  • Current cigarette smokers
  • Wiling to provide informed consent
  • Able to attend the lab session and abstain from tobacco/nicotine products as required
  • Agree to use designated products according to the study protocol

Exclusion Criteria

  • Women if they are breast-feeding or test positive for pregnancy (by urinalysis) at screening.
  • Individuals who weigh less than 110 pounds.

Some study details about the eligibility criteria are purposely omitted at this time to preserve scientific integrity. Full details will be posted at the conclusion of the study.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03861078). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search